Ciphergen Biosystems Inc..
This article was originally published in Start Up
Ciphergen Biosystems believes it has technology that is to proteins what PCR was to DNA. The start-up's technology uses silicon chips to help researchers capture proteins and look at the molecules in whatever state they prefer--either bound up in complexes or in increasingly purified forms.
You may also be interested in...
An ovarian cancer assay based on protein pattern analysis is arousing excitement in a field all too often met with disappointment. Given initial excitement over the test and protein pattern analysis in general, business activity is likely to follow shortly. The NCI, FDA and a start-up, Correlogic Systems, are developing the test and taking it to large clinical trials this summer. Correlogic claims to have broad patents on pattern analysis for diagnostic purposes, a contention that is sure to lead to controversy, given the apparently high stakes.
Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.